Pemetrexed in second line and beyond small cell lung cancer: A hoosier oncology group phase II study

Journal of Thoracic Oncology

Volumn 4, Issue 1, 2009, Pages 93-96

  Jalal, Shadia ^a,j   Ansari, Rafat ^b   Govindan, Ramaswamy ^c   Bhatia, Sumeet ^d   Bruetman, Daniel ^e   Fisher, William ^f   Masters, Gregory ^g   White, Angela ^h   Stover, Daniel ^h   Yu, Menggang ⁱ   Hanna, Nasser ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Northern Indiana Cancer Research Consortium   (United States)

^c USA   (United States)

^d Community Regional Cancer Center ^*  (United States)

^e Goshen Health System   (United States)

^f BALL MEMORIAL HOSPITAL   (United States)

^g CHRISTIANA CARE HEALTH SYSTEM   (United States)

^h Hoosier Oncology Group   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j NONE   (United States)

more..

Author keywords

Pemetrexed; Small cell lung cancer

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REPEATED DRUG DOSE; SEX RATIO; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA; DRUG ANTAGONISM; DRUG RESISTANCE; LUNG TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; PATHOLOGY; REMISSION; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NEUROENDOCRINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 61549083739     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31818de1e6     Document Type: Article

References (17)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small cell lung cancer in the United States over the past three decades: analysis of surveillance, epidemiologic and end results database. J Clin Oncol 2006;24:4539-4544.
2. Chute J, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.
3. O'Brien M, Ciuleanu T, Tsekov H, et al. Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC. Lung Cancer 2005;49(suppl 2):S54.
4. Morrison VA, Luikart SD. Chemotherapy of lung cancer. In MC Perry, ed. The Chemotherapy Source Book. Baltimore, MD: Williams and Wilkins, 1992. Pp. 932-947.
5. Stewart DJ, Dahrouge S, Soltys KM, Evans WK. A phase II study of 5-fluorouracil plus high-dose folinic acid in the treatment of recurrent small cell lung cancer. Am J Clin Oncol 1995;18:130-132.
6. Havsteen H, Sörenson S, Rørth M, Dombernowsky P, Hansen HH. 5-Fluorouracil in the treatment of small cell anaplastic carcinoma of the lung: a phase II trial. Cancer Treat Rep 1981;65:123-125.
7. Adjei AA. Pemetrexed (Alimta): a novel mutitargeted antifolate agent. Exp Rev Anticancer Ther 2003;3:145-156.
8. Chan DC, Chen VJ, Zhang Z, et al. Studies of pemetrexed and gemcit-abine, alone and in combinations, in human lung cancer models. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; Vol 24, No. 18S (June 20 suppl), 2006:17114.
9. Socinski MA, Weissman W, Hart LL, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006;24:4840-4847.
10. Grønberg BH, Bremnes RM, Aasebø U, et al. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer. 2008; doi:10.1016/j.lungcan. 2008.04.003.
11. Raju RN, Neubauer MA, Smith DA, et al. Pemetrexed (P) in relapsed small cell lung cancer (SCLC): preliminary results of a phase II trial. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings; Vol 25, No. 18S (June 20 suppl), 2007:7716.
12. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in che-monaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): interim results. 2008 ASCO Meeting.
13. Eismann U, Oberschmidt O, Ehnert M, et al. Thymidylate synthase gene expression in solid tumors predicts for response to pemetrexed in vitro. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; Vol 24, No. 18S (June 20 suppl), 2006:13058.
14. Scagliotti G, Park K, Patil S, et al. Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer. Eur J Cancer 2007;(suppl 5):363.
15. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed versus docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 2007;(suppl 5):363-364.
16. Ceppi P, Volante M, Ferrero A, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008;14:1059-1064.
17. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-7595.